Lara Krupka-Longpre

SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA.

MedGenesis Therapeutix, Inc. provides diagnostic product services. The private company is based in Victoria, Canada. The Canadian company was founded by Erich Mohr, Howard J. Federoff. Erich Mohr has been the CEO since incorporation.

PRA Health Sciences, Inc. engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. It operates through Clinical Research and Data Solutions segment. The Clinical Research segment serves biopharmaceutical clients and offers outsourced clinical research and clinical trial related services. The Data Solutions segment involves in data and analytics; technology solutions and real-world insights, and services primarily to the company's life science clients. The company was founded in 1976 and is headquartered in Raleigh, NC.